pcn poster

Posters

Mental Health Comorbidities Among Patients With Chronic Medical Conditions and Alcohol Use Disorder

The aim of this retrospective cohort study was to describe mental health comorbidities among patients with selected ambulatory-care sensitive conditions and comorbid alcohol use disorder ...

Lauren Strand , PhD, MS;

10/26/2023

Mobile Technology-Supported Shared Decision-Making and Goal Setting for Management of Depression in Primary Care

Mobile-based apps have potential to assist clinicians and patients in the shared decision-making (SDM) process for management of major depressive disorder (MDD). Primary Care Path is a pr...

Christina M. Hester , PhD, MPH;

10/26/2023

Multiple Factors Underlying Diagnostic Etiology of Psychosis: A Case Report.

27 year old male with history of HIV infection and substance abuse disorder arrived at the ER presenting aggressive behavior, errors of judgment and conduct, ego dystonic complex, auditor...

Patricio Mendoza Galvez , MD;

10/26/2023

No Signs of MDMA-Related Histopathological Changes to CNS in Rats and Dogs in A 28-Day Repeated Oral Dose Neurotoxicity Study

3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy is being investigated as a potential treatment option for patients with posttraumatic stress disorder (PTSD). Previous animal MDM...

Berra Yazar-Klosinski , PhD;

10/26/2023

Olanzapine/Samidorphan Effects on Weight Gain: A Pooled Analysis of Phase 2 and 3 Randomized, Double-Blind Studies

This pooled post hoc analysis compared the effects of a combination of olanzapine and samidorphan (OLZ/SAM) versus olanzapine on body weight after 12 weeks of treatment in patients with s...

Michael Doane , PhD;

10/26/2023

Long-term Safety, Tolerability, and Effectiveness of TV-46000, a Long-Acting Subcutaneous Antipsychotic (LASCA), in Patients With Schizophrenia (SHINE)

TV-46000 is a long-acting subcutaneous antipsychotic (LASCA). The SHINE study evaluated the long-term safety, tolerability, and effect of TV-46000 once monthly (q1m) and once every two mo...

Kelli R. Franzenburg , PhD;

10/26/2023

Lumateperone in the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: Evaluation of Extrapyramidal and Motor Symptoms in Late-Phase Clinical Trials

This analysis evaluated extrapyramidal symptoms (EPS) across 2 pooled, 6-week, placebo-controlled monotherapy studies; a 6-month open-label extension (OLE) monotherapy study; and a 6-week...

Margaret Martin , PharmD;

10/26/2023

Lumateperone Treatment for Major Depressive Episodes with Mixed Features in Major Depressive Disorder and Bipolar I or Bipolar II Disorder

This randomized, double-blind, placebo-controlled trial investigated the efficacy and safety of lumateperone 42mg for the treatment of a major depressive episode in patients with major de...

Suresh Durgam , MD;

10/26/2023

Maintenance Transcranial Magnetic Stimulation for Depression: A Meta-analysis

This meta-analysis aimed to assess the treatment effect of maintenance transcranial magnetic stimulation for depression. The analysis included 14 studies and 705 participants. Maintenance...

Fahad Mukhtar , MD, MPH;

10/26/2023

Long-Term Efficacy of Esketamine Nasal Spray Dosed in Accordance With US Prescribing Information in Adults With Treatment-Resistant Depression: A Subgroup Analysis of the SUSTAIN-3 Study Up to 6.5 Years

This subgroup analysis of SUSTAIN-3 (NCT02782104), a phase 3, open-label extension study of esketamine nasal spray (ESK), assessed the long-term efficacy of flexibly dosed ESK in combinat...

Toya Bowles , PharmD, MS, BCPP;

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products